Hemorrhagic Fever, Ebola: all 102 studies
Page 1 of 2. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the CongoNot yet recruitingNCT07842107Phase 2/3
- Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRCNot yet recruitingNCT07688083
- Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEANot yet recruitingNCT07681752
- A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General HealthRecruitingNCT07565090Phase 1
- EBOla Post-Exposure ProphylaxisNot yet recruitingNCT06841614Phase 3
- Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster DosesNot yet recruitingNCT06587503Phase 4
- Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCRecruitingNCT06126822Phase 3
- Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central UgandaRecruitingNCT06093646Not applicable
- Solidarity/Tokomeza Ebola TrialNot yet recruitingNCT05909358Phase 1/2
- Community Preparedness for Outbreak Response and Readiness for Ebola Vaccination in LiberiaNot yet recruitingNCT05888649
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy VolunteersNot yet recruitingNCT05202288Phase 2
- Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEPAvailableNCT05067166
- R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus DiseaseAvailableNCT03576690
- A Study of a New Vaccine Against Two Types of EbolaCompletedNCT05079750Phase 1Results posted
- Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)CompletedNCT04711356Phase 2Results posted
- Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against EbolaCompletedNCT04186000Phase 2Results posted
- Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy AdultsCompletedNCT04041570Phase 1Results posted
- A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in InfantsCompletedNCT03929757Phase 2Results posted
- Investigational Therapeutics for the Treatment of People With Ebola Virus DiseaseCompletedNCT03719586Phase 2/3Results posted
- A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)CompletedNCT03583606Phase 1Results posted
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-EbolaCompletedNCT03031912Phase 2Results posted
- Partnership for Research on Ebola VACcinationsCompletedNCT02876328Phase 2Results posted
- GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in SemenCompletedNCT02818582Phase 2Results posted
- Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-FiloTerminatedNCT02661464Phase 3Results posted
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-FiloCompletedNCT02598388Phase 2Results posted
- Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) AdultsCompletedNCT02564523Phase 2Results posted
- Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloCompletedNCT02509494Phase 3Results posted
- Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)CompletedNCT02503202Phase 3Results posted
- Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost VaccinationCompletedNCT02485912Phase 1Results posted
- A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsCompletedNCT02416453Phase 2Results posted
- STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)CompletedNCT02378753Phase 2/3Results posted
- Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola InfectionCompletedNCT02363322Phase 1/2Results posted
- Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)CompletedNCT02344407Phase 2Results posted
- Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in GuineaCompletedNCT02342171Phase 2/3Results posted
- Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)CompletedNCT02314923Phase 1Results posted
- Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)CompletedNCT02280408Phase 1Results posted
- Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)CompletedNCT02269423Phase 1Results posted
- Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in LiberiaCompletedNCT06811129
- Immunology of Ebola VaccineActive, not recruitingNCT06100913Phase 2
- REVIVE (Response to the Ebola Virus Vaccine)Active, not recruitingNCT05992480Phase 4
- Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for ExposureWithdrawnNCT05959421Phase 3
- Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL IIICompletedNCT05494801
- A Study in Tanzania of a New Vaccine Against Two Types of EbolaStatus unknownNCT05301504Phase 1
- Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone StudyCompletedNCT05284097Phase 2
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, GabonCompletedNCT05130398Phase 1/2
- Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)CompletedNCT05064956Phase 2
- INO-4201 as Booster in Healthy VSV-ZEBOV VaccineesCompletedNCT04906629Phase 1
- Prophylaxis Vaccine Antibodies EbolaStatus unknownNCT04822376Phase 2
- Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus DiseaseCompletedNCT04815174
- Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy AdultsCompletedNCT04723602Phase 1
- An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus DiseaseStatus unknownNCT04717830Phase 1
- Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)CompletedNCT04409405
- An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of EbolaWithdrawnNCT04268966Phase 2
- Piloting Clinical Bacteriology in the Ebola Virus Disease Care ResponseTerminatedNCT04250168
- Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRCStatus unknownNCT04235361
- Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCStatus unknownNCT04152486Phase 3
- ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)CompletedNCT04028349Phase 2
- EBOVAC-Salone ExtensionCompletedNCT03820739
- Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope GlycoproteinTerminatedNCT03462004Phase 1
- Providing Additional Information on the Safety and Effectiveness of an Ebola VaccineCompletedNCT03161366Phase 3
- Persistence of the Immune Response After Immunisation With Ebola Virus VaccinesCompletedNCT03140774
- PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine ResponseCompletedNCT03098862
- International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-CombiCompletedNCT03072030Phase 4
- Open Study of the Duration of Immunity After Vaccination With GamEvacCompletedNCT02911428
- Open Study of the Duration of Immunity After Vaccination With GamEvac-CombiCompletedNCT02911415
- A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy VolunteersCompletedNCT02891980Phase 1
- Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the SemenTerminatedNCT02739477Phase 2
- Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy AdultsCompletedNCT02718469Phase 1
- Efficacy of Favipiravir Against Severe Ebola Virus DiseaseCompletedNCT02662855Phase 2
- Evaluation of the FilmArray BioThreat-E TestCompletedNCT02658331
- A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease VaccineCompletedNCT02575456Phase 2
- Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsCompletedNCT02564575Phase 1
- A Booster Dose of Ad5-EBOV in Healthy Adults After Primary ImmunizationCompletedNCT02533791Phase 1
- A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOVCompletedNCT02495246Phase 1
- A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO ZTerminatedNCT02451891Phase 1
- Ebola Virus Disease Survivors: Clinical and Immunologic Follow-upCompletedNCT02431923
- A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.CompletedNCT02401373Phase 1
- Multiple Treatments for Ebola Virus Disease (EVD)Status unknownNCT02380625Phase 1/2
- Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus VaccineCompletedNCT02374385Phase 1
- Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy SubjectsCompletedNCT02370589Phase 1
- Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)CompletedNCT02368119Phase 1
- Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in UgandaCompletedNCT02354404Phase 1
- Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola TreatmentStatus unknownNCT02333578Not applicable
- Efficacy of Favipiravir Against Ebola (JIKI)CompletedNCT02329054Phase 2
- A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.CompletedNCT02326194Phase 1
- A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430CompletedNCT02319772Phase 1
- Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)WithdrawnNCT02307591Phase 2/3
- A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.Status unknownNCT02296983Phase 1
- A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus DiseaseTerminatedNCT02295501Phase 1
- A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in SwitzerlandCompletedNCT02289027Phase 1/2
- Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)CompletedNCT02283099Phase 1
- An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus DiseaseWithdrawnNCT02271347Phase 2
- Phase 1 Trial of Ebola Vaccine in MaliCompletedNCT02267109Phase 1
- A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® FiloCompletedNCT02240875Phase 1
- Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802TerminatedNCT02041715Phase 1
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult VolunteersWithdrawnNCT01593072Phase 1
- Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 InfusionTerminatedNCT01518881Phase 1
- Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola VirusCompletedNCT01353027Phase 1
- Evaluating an Ebola and a Marburg Vaccine in UgandaCompletedNCT00997607Phase 1
- Ebola and Marburg Virus VaccinesCompletedNCT00605514Phase 1